Lightlake Therapeutics is a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists. The company holds patents covering the use of intranasal naloxone to treat binge eating disorder (BED) and patents covering drug addiction. Lightlake is focused on advancing its BED treatment and also planning a clinical trial for the indication of bulimia nervosa. The company is also applying its technology to develop a treatment for managing the complications of opioid drug addiction. For more information, visit the company’s website at www.lightlaketherapeutics.com.